UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

           March 12, 2008           
(Date of earliest event reported)

LABORATORY CORPORATION OF
AMERICA HOLDINGS

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01. Regulation FD Disclosure

On March 12, 2008, Laboratory Corporation of America^® Holdings (LabCorp^®) (NYSE: LH) announced that David P. King, Chief Executive Officer and Bradford T. Smith, Executive Vice President, Corporate Affairs, are scheduled to speak at the Cowen and Company 28^th Annual Health Care Conference in Boston, MA. LabCorp’s presentation is planned for Tuesday, March 18, 2008 at 1:40 p.m. (Eastern Time).

Exhibits

99.1 Press Release dated March 12, 2008

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Laboratory Corporation of America Holdings (Registrant)
Date: March 12, 2008	By:	/s/Bradford T. Smith
		Bradford T. Smith, Executive Vice President and Secretary